相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A Quality-Adjusted Survival (Q-TWiST) Analysis to Assess Benefit-Risk of Acalabrutinib Versus Idelalisib/Bendamustine Plus Rituximab or Ibrutinib Among Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) Patients
John F. Seymour et al.
BLOOD (2021)
Acalabrutinib in treatment-naive chronic lymphocytic leukemia
John C. Byrd et al.
BLOOD (2021)
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
John C. Byrd et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202
Amy S. Ruppert et al.
LEUKEMIA (2021)
Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib?
Alessandra Tedeschi et al.
BLOOD ADVANCES (2021)
Ibrutinib-Mediated Atrial Fibrillation Attributable to Inhibition of C-Terminal Src Kinase
Ling Xiao et al.
CIRCULATION (2020)
Managing toxicities of Bruton tyrosine kinase inhibitors
Andrew Lipsky et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2020)
Adverse Event Burden Score-A Versatile Summary Measure for Cancer Clinical Trials
Jennifer G. Le-Rademacher et al.
CANCERS (2020)
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab
John C. Byrd et al.
BLOOD (2019)
Ibrutinib increases the risk of hypertension and atrial fibrillation: Systematic review and meta-analysis
Daniel Caldeira et al.
PLOS ONE (2019)
Targeting BTK in CLL: Beyond Ibrutinib
David A. Bond et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2019)
Hypertension and incident cardiovascular events following ibrutinib initiation
Tyler Dickerson et al.
BLOOD (2019)
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis
Anthony R. Mato et al.
HAEMATOLOGICA (2018)
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis
Anthony R. Mato et al.
HAEMATOLOGICA (2018)
Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies
Gita Thanarajasingam et al.
LANCET HAEMATOLOGY (2018)
The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia
Sarah E. M. Herman et al.
CLINICAL CANCER RESEARCH (2017)
Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells
Viralkumar Patel et al.
CLINICAL CANCER RESEARCH (2017)
Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile
Tjeerd Barf et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2017)
Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib
Alexander P. Bye et al.
BLOOD ADVANCES (2017)
Current understanding of bleeding with ibrutinib use: a systematic review and meta-analysis
Francois Caron et al.
BLOOD ADVANCES (2017)
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling
Julie R. McMullen et al.
BLOOD (2014)
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765)
Jan A. Burger et al.
LEUKEMIA & LYMPHOMA (2013)
分享论文
